ALK and non-small cell lung carcinoma: CheckMate 9LA is a phase 3 randomized controlled trial evaluating the efficacy of the combination of ipilimumab plus nivolumab plus chemotherapy compared to chemotherapy alone as first-line treatment in metastatic or recurrent NSCLC without EGFR/ALK alterations.